Abl (Q252H), active Human Recombinant Kinase Protein
10 µg of active Abl (Q252H). N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation.
No items found.
Biological information
Background
N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Target class
Kinase
Family
TK
Accession number
NM_005157.3; NM_007313.2
Target Name
Abl (Q252H), active Human Recombinant Kinase Protein
Target Alias
ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL
Origin
Human
Theori. MW
121 kDa
Affinity tag
6His
Product specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Purity 51% by SDS-PAGE and Coomassie staining.
Purification method
Ni2+/NTA-agarose
Sample Buffer
Protein in 50 mM Tris/HCl pH7.5, 150 mM NaCl, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.
Specified activity
Refer to CoA
Application
For Research Only
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only
Chemical data
Background
N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Compound name
Kinase
Catalog number
14-751
Molecular formula
CAS
MW
Ka
Percent composition
Product specifications
Physical state
Purity (HPLC 214nm)
Retention time (RP18 HPLC)
CMC
Exact mass
Stability
For Research Only
Solubility structure
Lipid Kinase Activity Assay Biological information
Background
N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Target class
Kinase
Family
TK
Subfamily
Protein Name
Abl
Protein Alias
ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL
Accession Number
NM_005157.3; NM_007313.2
UniProt Number
Gene Name
Gene ID
Gene Aliases
Target Species
Human
Lipid Kinase Activity Assay Usage
Product Type
Application
Storage Conditions
6 months at -70°C
Usage disclaimer
Lipid Kinase Activity Assay Information
Assay Type
Assay Measures
Biological Information
Background
N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Target class
Kinase
Family
TK
Accession Number
NM_005157.3; NM_007313.2
Target Name
Abl
Target Alias
ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL
Origin
Human
Theoretical MW
Affinity Tag
6His
Product Specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Purity 51% by SDS-PAGE and Coomassie staining.
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only
Biological Information
Background
N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Target class
Kinase
Family
TK
Accession Number
NM_005157.3; NM_007313.2
Target Name
Abl
Target Alias
ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL
Origin
Human
Theoretical MW
Affinity Tag
6His
Product Specifications
Expression system
Expressed by baculovirus in Sf21 insect cells
Purity
Purity 51% by SDS-PAGE and Coomassie staining.
Purification method
Ni2+/NTA-agarose
Sample Buffer
Specified activity
Refer to CoA
Application
Storage conditions
6 months at -70°C
Usage disclaimer
For Research Only